Xilio Therapeutics, Inc. Operating Cash Flow
Xilio Therapeutics, Inc. (XLO) reported Operating Cash Flow of -$41.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.76M.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$22.34M, a 177.10% decline year-over-year.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.00M.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.50M.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$4.99M.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$18.38M.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$68.62M.
- Xilio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$75.72M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$41.10M 10-Q · filed 2026-08-12 | -$43.10M derived: sum of 3 quarters · filed 2026-08-12 | -$60.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$22.34M 10-Q · filed 2026-05-12 | -$24.34M derived: sum of 2 quarters · filed 2026-05-12 | -$41.84M derived: sum of 3 quarters · filed 2026-05-12 | -$56.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$19.49M derived: sum of 2 quarters · filed 2026-03-23 | -$33.97M derived: sum of 3 quarters · filed 2026-08-12 | -$4.99M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$17.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$31.97M derived: sum of 2 quarters · filed 2026-08-12 | -$2.99M 10-Q · filed 2025-11-13 | -$17.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$14.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $14.50M 10-Q · filed 2026-08-12 | $344.00K derived: sum of 3 quarters · filed 2026-08-12 | -$13.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $28.98M 10-Q · filed 2026-05-12 | $14.82M derived: sum of 2 quarters · filed 2026-05-12 | $1.15M derived: sum of 3 quarters · filed 2026-05-12 | $21.10M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$14.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$27.83M derived: sum of 2 quarters · filed 2026-03-23 | -$7.88M derived: sum of 3 quarters · filed 2026-03-23 | -$18.38M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$13.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.28M derived: sum of 2 quarters · filed 2025-11-13 | -$4.22M 10-Q · filed 2025-11-13 | -$17.65M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $19.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $9.45M 10-Q · filed 2025-08-14 | -$3.98M derived: sum of 3 quarters · filed 2025-08-14 | -$17.34M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$10.50M 10-Q · filed 2025-05-08 | -$23.93M derived: sum of 2 quarters · filed 2025-05-08 | -$37.30M derived: sum of 3 quarters · filed 2025-05-08 | -$53.87M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$13.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$26.80M derived: sum of 2 quarters · filed 2025-03-11 | -$43.37M derived: sum of 3 quarters · filed 2025-03-11 | -$68.62M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$13.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$29.94M derived: sum of 2 quarters · filed 2024-11-07 | -$55.19M 10-Q · filed 2024-11-07 | -$73.42M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$16.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$41.82M 10-Q · filed 2024-08-08 | -$60.05M derived: sum of 3 quarters · filed 2024-08-08 | -$79.96M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$25.25M 10-Q · filed 2024-05-14 | -$43.47M derived: sum of 2 quarters · filed 2024-05-14 | -$63.38M derived: sum of 3 quarters · filed 2024-05-14 | -$80.14M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$18.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$38.13M derived: sum of 2 quarters · filed 2024-04-01 | -$54.89M derived: sum of 3 quarters · filed 2024-04-01 | -$75.72M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$19.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$36.66M derived: sum of 2 quarters · filed 2023-11-09 | -$57.50M 10-Q · filed 2023-11-09 | -$74.66M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$16.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$37.59M 10-Q · filed 2023-08-14 | -$54.75M derived: sum of 3 quarters · filed 2023-08-14 | -$75.47M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$20.84M 10-Q · filed 2023-05-09 | -$38.00M derived: sum of 2 quarters · filed 2023-05-09 | -$58.72M derived: sum of 3 quarters · filed 2023-05-09 | -$78.85M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$17.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$37.88M derived: sum of 2 quarters · filed 2023-03-02 | -$58.02M derived: sum of 3 quarters · filed 2023-03-02 | -$80.75M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$20.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$40.85M derived: sum of 2 quarters · filed 2022-11-09 | -$63.59M 10-Q · filed 2022-11-09 | -$76.29M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$20.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$42.87M 10-Q · filed 2022-08-09 | -$55.58M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$22.73M 10-Q · filed 2022-05-12 | -$35.44M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$12.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$36.09M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | -$23.39M 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |